ENGOT-en9/LEAP-001: A phase III study of first-line pembrolizumab plus lenvatinib versus chemotherapy in advanced or recurrent endometrial cancer.

Simple item page
dc.contributor.authorMarth, Christian
dc.contributor.authorVulsteke, Christof
dc.contributor.authorPerez, Maria Jesus Rubio
dc.contributor.authorMakker, Vicky
dc.contributor.authorBraicu, Elena Ioana
dc.contributor.authorMcNeish, Iain A.
dc.contributor.authorMadry, Radoslaw
dc.contributor.authorAyhan, Ali
dc.contributor.authorHasegawa, Kosei
dc.contributor.authorWu, Xiaohua
dc.contributor.authorDutta, Lea
dc.contributor.authorXu, Cindy
dc.contributor.authorKeefe, Stephen Michael
dc.contributor.authorLee, John J.
dc.contributor.authorPignata, Sandro
dc.date.accessioned2021-03-05T09:09:44Z
dc.date.available2021-03-05T09:09:44Z
dc.date.issued2020
dc.description.sponsorshipAmer Soc Clin Oncolen_US
dc.identifier.issn0732-183Xen_US
dc.identifier.issue15en_US
dc.identifier.urihttp://hdl.handle.net/11727/5511
dc.identifier.volume38en_US
dc.identifier.wos000560368309198en_US
dc.language.isoengen_US
dc.relation.journalJOURNAL OF CLINICAL ONCOLOGYen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleENGOT-en9/LEAP-001: A phase III study of first-line pembrolizumab plus lenvatinib versus chemotherapy in advanced or recurrent endometrial cancer.en_US
dc.typeConference Objecten_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Tıp Fakültesi / Faculty of Medicine
Wos İndeksli Yayınlar Koleksiyonu
Wos Kapalı Erişimli Yayınlar